Tag: Apnimed

NORTHFIELD, Ill. – Medline has launched a new Food Benefit Solution that allows Medicare Advantage and Managed Medicaid Organizations to offer locally sourced and fresh produce, healthy groceries and prepared meals – delivered directly to member homes – as an added supplemental benefit.  “Access to a food benefit can help members meet their nutritional needs, encourage healthier eating habits, and manage and prevent chronic diseases,” said Amy Rogers, BSN, RN,...

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea, has announced a joint venture with Shionogi & Co., a pharmaceutical company based in Japan, to develop therapies to treat OSA and other sleep disorders. The joint venture, Shionogi-Apnimed Sleep Science, combines Apnimed’s deep knowledge of OSA, highly experienced clinical-stage drug development team and robust network of...

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, has appointed John Yee, MD, MPH, as senior vice president of medical affairs. Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about the company’s lead drug candidate AD109, as well as other pipeline assets, as they progress through clinical development toward commercial launch....

CAMBRIDGE, Mass. – Apnimed has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The company will use proceeds to fund the planned Phase 3 trials for its lead candidate, AD 109 (aroxybutynin + atomoxetine), which has the potential to be the first oral treatment for obstructive sleep apnea. “This substantial additional investment is a significant vote of confidence by our investors,” said Larry Miller, M.D.,...

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, has announced positive topline results from the MARIPOSA Phase 2b trial – an efficacy, safety and dose-finding study of one-month duration. The results were positive for the company’s lead candidate for OSA, AD109 (atomoxetine + aroxybutynin). The primary endpoint showed a statistically significant...

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182. Patients treated with AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in AHI from placebo, which...